Dr. Stephen E. Spurgeon
Claim this profileOHSU Knight Cancer Institute
Studies Lymphoma
Studies Non-Hodgkin's Lymphoma
6 reported clinical trials
12 drugs studied
Area of expertise
1Lymphoma
Stage IV
Stage III
CCND1 positive
2Non-Hodgkin's Lymphoma
Stage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Stephen E. Spurgeon is currently running
PRO1160
for Advanced Cancer
This trial tests PRO1160, a targeted cancer treatment, in patients with advanced or hard-to-remove cancers. PRO1160 uses an antibody to find cancer cells and a drug to kill them.
Recruiting1 award Phase 1 & 25 criteria
Mosunetuzumab + Chemotherapy
for Diffuse Large B-Cell Lymphoma
This phase Ib/II clinical trial tests the safety, side effects, and effectiveness of mosunetuzumab with chemotherapy for the treatment of patients with untreated, c-Myc rearrangement positive, high grade B cell lymphoma or diffuse large B cell lymphoma. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as mosunetuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as etoposide, doxorubicin, vincristine, cyclophosphamide and prednisone work in different ways to stop the growth of cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving mosunetuzumab with chemotherapy may be safe, tolerable and/or effective in treating patients with untreated, c-Myc rearrangement positive, high grade B cell lymphoma or diffuse large B cell lymphoma.
Recruiting1 award Phase 1 & 2
More about Stephen E. Spurgeon
Clinical Trial Related6 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Stephen E. Spurgeon has experience with
- Obinutuzumab
- Ibrutinib
- Acalabrutinib
- Chemotherapy
- Mosunetuzumab
- Glofitamab
Breakdown of trials Stephen E. Spurgeon has run
Lymphoma
Non-Hodgkin's Lymphoma
Mantle Cell Lymphoma
Childhood Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Stephen E. Spurgeon specialize in?
Stephen E. Spurgeon focuses on Lymphoma and Non-Hodgkin's Lymphoma. In particular, much of their work with Lymphoma has involved Stage IV patients, or patients who are Stage III.
Is Stephen E. Spurgeon currently recruiting for clinical trials?
Yes, Stephen E. Spurgeon is currently recruiting for 3 clinical trials in Portland Oregon. If you're interested in participating, you should apply.
Are there any treatments that Stephen E. Spurgeon has studied deeply?
Yes, Stephen E. Spurgeon has studied treatments such as Obinutuzumab, Ibrutinib, Acalabrutinib.
What is the best way to schedule an appointment with Stephen E. Spurgeon?
Apply for one of the trials that Stephen E. Spurgeon is conducting.
What is the office address of Stephen E. Spurgeon?
The office of Stephen E. Spurgeon is located at: OHSU Knight Cancer Institute, Portland, Oregon 97239 United States. This is the address for their practice at the OHSU Knight Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.